These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16155018)

  • 1. Identification and validation of novel therapeutic targets for multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Anderson KC
    J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
    Anderson KC
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The malignant clone and the bone-marrow environment.
    Podar K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):597-612. PubMed ID: 18070708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel biological therapies for the treatment of multiple myeloma.
    Richardson PG; Mitsiades CS; Hideshima T; Anderson KC
    Best Pract Res Clin Haematol; 2005; 18(4):619-34. PubMed ID: 16026741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
    Hideshima T; Anderson KC
    Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenomics to target myeloma in the bone marrow microenvironment.
    Anderson KC
    Clin Cancer Res; 2011 Mar; 17(6):1225-33. PubMed ID: 21411438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
    Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
    Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
    Yasui H; Hideshima T; Richardson PG; Anderson KC
    Br J Haematol; 2006 Feb; 132(4):385-97. PubMed ID: 16412014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
    Mitsiades CS; Mitsiades NS; Richardson PG; Munshi NC; Anderson KC
    J Cell Biochem; 2007 Jul; 101(4):950-68. PubMed ID: 17546631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the biology of multiple myeloma: therapeutic applications.
    Anderson K
    Semin Oncol; 1999 Oct; 26(5 Suppl 13):10-22. PubMed ID: 10528890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
    Catley L; Tai YT; Chauhan D; Anderson KC
    Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
    San Miguel J
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hematopoietic stem cell transplantation in multiple myeloma].
    Vela-Ojeda J; Ruiz-Esparza MA
    Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of multiple myeloma].
    Di Raimondo F; Pennisi A; Bari A; Fiumara P; Palumbo GA
    G Ital Nefrol; 2005; 22 Suppl 33():S46-52. PubMed ID: 16419006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.
    Mehta J; Singhal S
    Bone Marrow Transplant; 2007 Dec; 40(12):1101-14. PubMed ID: 17680020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
    Campbell RA; Manyak SJ; Yang HH; Sjak-Shie NN; Chen H; Gui D; Popoviciu L; Wang C; Gordon M; Pang S; Bonavida B; Said J; Berenson JR
    Int J Oncol; 2006 Jun; 28(6):1409-17. PubMed ID: 16685443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.